{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:15:54Z","timestamp":1790687754476,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T00:00:00Z","timestamp":1658361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T00:00:00Z","timestamp":1658361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Islet transplantation is a unique paradigm in organ transplantation, since multiple donors are required to achieve complete insulin-independence. Preformed or de novo Donor Specific Antibodies (DSA) may target one or several donor islets, which adds complexity to the analysis of their impact. Adult patients with type 1 diabetes transplanted with pancreatic islets between 2005 and 2018 were included in a single-center observational study. Thirty-two recipients with available sera tested by solid-phase assays for anti-HLA antibodies during their whole follow-up were analyzed. Twenty-five recipients were islet-transplantation-alone recipients, and 7 islet-after-kidney recipients. Seven recipients presented with DSA at any time during follow-up (two with preformed DSA only, one with preformed and de novo DSA, 4 with de novo DSA only). Only islet-transplantation-alone recipients presented with de novo DSA. Three clinical trajectories were identified according to: 1\/the presence of preformed DSA, 2\/early de novo DSA or 3\/late de novo DSA. Only late de novo DSA were associated with unfavorable outcomes, depicted by a decrease of the \u03b2-score. Islet transplantation with preformed DSA, even with high MFI values, is associated with favorable outcomes in our experience. On the contrary, de novo DSA, and especially late de novo DSA, may be associated with allograft loss.<\/jats:p>","DOI":"10.1038\/s41598-022-16782-3","type":"journal-article","created":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T11:03:02Z","timestamp":1658401382000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The challenge of HLA donor specific antibodies in the management of pancreatic islet transplantation: an illustrative case-series"],"prefix":"10.1038","volume":"12","author":[{"given":"Mehdi","family":"Maanaoui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Chetboun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Top","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Elsermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Kerr-Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristell","family":"Le Mapihan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederique","family":"Defrance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9ry","family":"Gmyr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Labalette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Hazzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Christine","family":"Vantyghem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Pattou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,21]]},"reference":[{"key":"16782_CR1","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/S2213-8587(18)30078-0","volume":"6","author":"S Lablanche","year":"2018","unstructured":"Lablanche, S. et al. Islet transplantation versus insulin therapy in patients with type 1 diabetes with severe hypoglycaemia or poorly controlled glycaemia after kidney transplantation (TRIMECO): A multicentre, randomised controlled trial. Lancet Diabetes Endocrinol. 6, 527\u2013537 (2018).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"16782_CR2","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1097\/MOT.0b013e32834c2393","volume":"16","author":"B Nilsson","year":"2011","unstructured":"Nilsson, B., Ekdahl, K. N. & Korsgren, O. Control of instant blood-mediated inflammatory reaction to improve islets of Langerhans engraftment. Curr. Opin. Organ Transplant. 16, 620\u2013626 (2011).","journal-title":"Curr. Opin. Organ Transplant."},{"key":"16782_CR3","doi-asserted-by":"crossref","unstructured":"Eich, T., Eriksson, O., Lundgren, T., & Nordic Network for Clinical Islet Transplantation. Visualization of early engraftment in clinical islet transplantation by positron-emission tomography. N Engl. J. Med. 356, 2754\u20132755 (2007).","DOI":"10.1056\/NEJMc070201"},{"key":"16782_CR4","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.2337\/dc15-1988","volume":"39","author":"BJ Hering","year":"2016","unstructured":"Hering, B. J. et al. Phase 3 trial of transplantation of human islets in type 1 diabetes complicated by severe hypoglycemia. Diabetes Care 39, 1230\u20131240 (2016).","journal-title":"Diabetes Care"},{"key":"16782_CR5","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.2337\/dc19-0401","volume":"42","author":"M-C Vantyghem","year":"2019","unstructured":"Vantyghem, M.-C. et al. Ten-year outcome of islet alone or islet after kidney transplantation in type 1 diabetes: A prospective parallel-arm cohort study. Diabetes Care 42, 2042\u20132049 (2019).","journal-title":"Diabetes Care"},{"key":"16782_CR6","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.2337\/dc08-1685","volume":"32","author":"M-C Vantyghem","year":"2009","unstructured":"Vantyghem, M.-C. et al. Primary graft function, metabolic control, and graft survival after islet transplantation. Diabetes Care 32, 1473\u20131478 (2009).","journal-title":"Diabetes Care"},{"key":"16782_CR7","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1056\/NEJMra1802677","volume":"379","author":"A Loupy","year":"2018","unstructured":"Loupy, A. & Lefaucheur, C. Antibody-mediated rejection of solid-organ allografts. N Engl. J. Med. 379, 1150\u20131160 (2018).","journal-title":"N Engl. J. Med."},{"key":"16782_CR8","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1681\/ASN.2009101065","volume":"21","author":"C Lefaucheur","year":"2010","unstructured":"Lefaucheur, C. et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J. Am. Soc. Nephrol. 21, 1398\u20131406 (2010).","journal-title":"J. Am. Soc. Nephrol."},{"key":"16782_CR9","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s00125-015-3779-1","volume":"59","author":"CR van der Torren","year":"2016","unstructured":"van der Torren, C. R. et al. Innate and adaptive immunity to human beta cell lines: Implications for beta cell therapy. Diabetologia 59, 170\u2013175 (2016).","journal-title":"Diabetologia"},{"key":"16782_CR10","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/j.1365-2249.2012.04605.x","volume":"169","author":"VAL Huurman","year":"2012","unstructured":"Huurman, V. A. L. et al. Immune responses against islet allografts during tapering of immunosuppression - a pilot study in 5 subjects: Immunosuppression in islet cell transplantation. Clin. Exp. Immunol. 169, 190\u2013198 (2012).","journal-title":"Clin. Exp. Immunol."},{"key":"16782_CR11","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.2337\/db12-1802","volume":"62","author":"MR Rickels","year":"2013","unstructured":"Rickels, M. R. et al. Improvement in \u03b2-Cell secretory capacity after human islet transplantation according to the CIT07 protocol. Diabetes 62, 2890\u20132897 (2013).","journal-title":"Diabetes"},{"key":"16782_CR12","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.2337\/db12-1258","volume":"62","author":"L Piemonti","year":"2013","unstructured":"Piemonti, L. et al. Alloantibody and autoantibody monitoring predicts islet transplantation outcome in human type 1 diabetes. Diabetes 62, 1656\u20131664 (2013).","journal-title":"Diabetes"},{"key":"16782_CR13","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/ajt.13936","volume":"17","author":"E Pouliquen","year":"2017","unstructured":"Pouliquen, E. et al. Anti-donor HLA antibody response after pancreatic islet grafting: Characteristics, risk factors, and impact on graft function. Am. J. Transplant 17, 462\u2013473 (2017).","journal-title":"Am. J. Transplant"},{"key":"16782_CR14","unstructured":"CNIL. D\u00e9lib\u00e9ration n\u00b0 2018\u2013155 du 3 mai 2018 portant homologation de la m\u00e9thodologie de r\u00e9f\u00e9rence relative aux traitements de donn\u00e9es \u00e0 caract\u00e8re personnel mis en \u0153uvre dans le cadre des recherches n\u2019impliquant pas la personne humaine, des \u00e9tudes et \u00e9valuations dans le domaine de la sant\u00e9 (MR-004). (2018). https:\/\/www.legifrance.gouv.fr\/jorf\/id\/JORFTEXT000037187498."},{"key":"16782_CR15","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1111\/ajt.14514","volume":"18","author":"K Benomar","year":"2018","unstructured":"Benomar, K. et al. Purity of islet preparations and 5-year metabolic outcome of allogenic islet transplantation. Am. J. Transplant. 18, 945\u2013951 (2018).","journal-title":"Am. J. Transplant."},{"key":"16782_CR16","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2337\/diacare.28.2.343","volume":"28","author":"EA Ryan","year":"2005","unstructured":"Ryan, E. A. et al. Score: An assessment of -cell function after islet transplantation. Diabetes Care 28, 343\u2013347 (2005).","journal-title":"Diabetes Care"},{"key":"16782_CR17","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1681\/ASN.2016070797","volume":"28","author":"O Aubert","year":"2017","unstructured":"Aubert, O. et al. Antibody-mediated rejection due to preexisting versus De Novo donor-specific antibodies in kidney allograft recipients. JASN 28, 1912\u20131923 (2017).","journal-title":"JASN"},{"key":"16782_CR18","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/TP.0b013e31817ba628","volume":"86","author":"S Ferrari-Lacraz","year":"2008","unstructured":"Ferrari-Lacraz, S. et al. Low risk of anti-human leukocyte antigen antibody sensitization after combined kidney and islet transplantation. Transplantation 86, 357\u2013359 (2008).","journal-title":"Transplantation"},{"key":"16782_CR19","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1097\/TP.0b013e3182977afc","volume":"96","author":"R Hilbrands","year":"2013","unstructured":"Hilbrands, R. et al. Predictive factors of allosensitization after immunosuppressant withdrawal in recipients of long-term cultured islet cell grafts. Transpl. J. 96, 162\u2013169 (2013).","journal-title":"Transpl. J."},{"key":"16782_CR20","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1111\/ajt.13407","volume":"15","author":"AMS Brooks","year":"2015","unstructured":"Brooks, A. M. S. et al. De Novo Donor-specific HLA antibodies are associated with rapid loss of graft function following islet transplantation in type 1 diabetes: DSA leads to rapid loss of islet transplant function. Am. J. Transplant. 15, 3239\u20133246 (2015).","journal-title":"Am. J. Transplant."},{"key":"16782_CR21","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.3727\/096368916X691673","volume":"25","author":"B Chaigne","year":"2016","unstructured":"Chaigne, B. et al. Immunogenicity of anti-HLA antibodies in pancreas and islet transplantation. Cell Transpl. 25, 2041\u20132050 (2016).","journal-title":"Cell Transpl."},{"key":"16782_CR22","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1172\/JCI93542","volume":"128","author":"C-C Chen","year":"2017","unstructured":"Chen, C.-C. et al. Endothelial chimerism and vascular sequestration protect pancreatic islet grafts from antibody-mediated rejection. J. Clin. Investig. 128, 219\u2013232 (2017).","journal-title":"J. Clin. Investig."},{"key":"16782_CR23","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/S1262-3636(06)72805-1","volume":"32","author":"S Reffet","year":"2006","unstructured":"Reffet, S. & Thivolet, C. Immunology of pancreatic islet transplantation. Diabetes Metab. 32, 523\u2013526 (2006).","journal-title":"Diabetes Metab."},{"key":"16782_CR24","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S0140-6736(19)31334-0","volume":"394","author":"M-C Vantyghem","year":"2019","unstructured":"Vantyghem, M.-C., de Koning, E. J. P., Pattou, F. & Rickels, M. R. Advances in \u03b2-cell replacement therapy for the treatment of type 1 diabetes. The Lancet 394, 1274\u20131285 (2019).","journal-title":"The Lancet"},{"key":"16782_CR25","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1097\/TP.0b013e3181bc06b0","volume":"88","author":"C Toso","year":"2009","unstructured":"Toso, C. et al. Histologic Graft assessment after clinical islet transplantation. Transplantation 88, 1286\u20131293 (2009).","journal-title":"Transplantation"},{"key":"16782_CR26","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/NEJMc0802893","volume":"359","author":"GT Westermark","year":"2008","unstructured":"Westermark, G. T., Westermark, P., Berne, C. & Korsgren, O. Widespread amyloid deposition in transplanted human pancreatic islets. N Engl. J. Med. 359, 977\u2013979 (2008).","journal-title":"N Engl. J. Med."},{"key":"16782_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0002435","volume":"3","author":"VAL Huurman","year":"2008","unstructured":"Huurman, V. A. L. et al. Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation. PLoS ONE 3, e2435 (2008).","journal-title":"PLoS ONE"},{"key":"16782_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16174","author":"J Markmann","year":"2020","unstructured":"Markmann, J. et al. Phase 3 trial of human islet-after-kidney transplantation in type 1 diabetes. Am. J. Transplant https:\/\/doi.org\/10.1111\/ajt.16174 (2020).","journal-title":"Am. J. Transplant"},{"key":"16782_CR29","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/01.TP.0000164143.22287.E3","volume":"80","author":"CA van Kampen","year":"2005","unstructured":"van Kampen, C. A. et al. Alloreactivity against repeated hla mismatches of sequential islet grafts transplanted in non-uremic type 1 diabetes patients. Transplantation 80, 118\u2013126 (2005).","journal-title":"Transplantation"},{"key":"16782_CR30","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1111\/tri.13930","volume":"34","author":"L Piemonti","year":"2021","unstructured":"Piemonti, L. et al. US food and drug administration (FDA) panel endorses islet cell treatment for type 1 diabetes: A pyrrhic victory?. Transpl. Int. 34, 1182\u20131186 (2021).","journal-title":"Transpl. Int."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-16782-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-16782-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-16782-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T23:34:25Z","timestamp":1669332865000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-16782-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,21]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["16782"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-16782-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,21]]},"assertion":[{"value":"28 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12463"}}